Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;17(6):e13148.
doi: 10.1111/irv.13148.

Influenza-like illness in individuals treated with immunosuppressants, biologics, and/or systemic corticosteroids for autoimmune or chronic inflammatory disease: A crowdsourced cohort study, France, 2017-2018

Ségolène Greffe  1 , Caroline Guerrisi  2 , Cécile Souty  2 , Ana-Maria Vilcu  2 , Gilles Hayem  3   4 , Félicie Costantino  3   5   6 , Ilaria Padovano  3 , Isabelle Bourgault  5   7 , Salim Trad  1 , Matthieu Ponsoye  1   5   8 , Eve Vilaine  9 , Marion Debin  2 , Clément Turbelin  2 , Thierry Blanchon  2 , Thomas Hanslik  1   5
Affiliations

Influenza-like illness in individuals treated with immunosuppressants, biologics, and/or systemic corticosteroids for autoimmune or chronic inflammatory disease: A crowdsourced cohort study, France, 2017-2018

Ségolène Greffe et al. Influenza Other Respir Viruses. 2023 Jun.

Abstract

Background: Influenza-like illness (ILI) incidence estimates in individuals treated with immunosuppressants and/or biologics and/or corticosteroid for an autoimmune or chronic inflammatory disease are scarce. We compared the ILI incidence among immunocompromised population and the general population.

Method: We conducted a prospective cohort study during the 2017-2018 seasonal influenza epidemic, on the GrippeNet.fr electronic platform, which allows the collection of epidemiological crowdsourced data on ILI, directly from the French general population. The immunocompromised population were adults treated with systemic corticosteroids, immunosuppressants, and/or biologics for an autoimmune or chronic inflammatory disease, recruited directly on GrippeNet.fr and also among patients of the departments of a single university hospital that were asked to incorporate GrippeNet.fr. The general population consisted of adults reporting none of the above treatments or diseases participating in GrippeNet.fr. The incidence of ILI was estimated on a weekly basis and compared between the immunocompromised population and the general population, during the seasonal influenza epidemic.

Results: Among the 318 immunocompromised patients assessed for eligibility, 177 were included. During the 2017-2018 seasonal influenza epidemic period, immunocompromised population had 1.59 (95% CI: 1.13-2.20) higher odds to experience an ILI episode, compared to the general population (N = 5358). An influenza vaccination was reported by 58% of the immunocompromised population, compared to 41% of the general population (p < 0.001).

Conclusion: During a seasonal influenza epidemic period, the incidence of influenza-like illness was higher in patients treated with immunosuppressants, biologics, and/or corticosteroids for an autoimmune or chronic inflammatory disease, compared to the general population.

Keywords: crowdsourcing; epidemiological monitoring; immunocompromised patients; influenza incidence; influenza vaccine.

PubMed Disclaimer

Conflict of interest statement

No financial or non‐financial benefits have been received or will be received from any party directly or indirectly related to this article's subject.

Figures

FIGURE 1
FIGURE 1
Flowchart of the study.
FIGURE 2
FIGURE 2
Weekly ILI incidence, in immunocompromised individuals (GrippeNet.fr platform) and in primary care (Sentinelles network), 2017–2018 season.
FIGURE 3
FIGURE 3
Weekly incidence of ILI episodes reported on the GrippeNet.fr platform, in immunocompromised individuals and the general population, 2017–2018 season.
See this image and copyright information in PMC

References

    1. Duchet‐Niedziolka P, Hanslik T, Mouthon L, Guillevin L, Launay O. Flu vaccine and auto‐immune and/or inflammatory diseases. Presse Medicale (Paris, France: 1983). 2011;40(3):248‐252. - PubMed
    1. Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5(2):e001041. doi: 10.1136/rmdopen-2019-001041 - DOI - PMC - PubMed
    1. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza‐related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13(1):158. doi: 10.1186/1471-2474-13-158 - DOI - PMC - PubMed
    1. Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenza‐like symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5):359‐365. doi: 10.3109/03009742.2012.670729 - DOI - PubMed
    1. Bello SL, Serafino L, Bonali C, et al. Incidence of influenza‐like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299‐306. doi: 10.4081/reumatismo.2012.299 - DOI - PubMed

Publication types